Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01950598
Other study ID # FvF 08.275
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 2013
Est. completion date November 2020

Study information

Verified date January 2021
Source Centre hospitalier de l'Université de Montréal (CHUM)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether frozen corneas are as safe and effective as fresh corneas for use as carriers with the Boston Keratoprosthesis type I (KPro) over long term follow-up. Corneal transplantation is typically performed using fresh, transparent corneas. With KPro surgery, the corneal transplant only serves as a carrier to suture the KPro in place. The cornea used in KPro surgery does not need to be clear like a normal transplant. Frozen corneal tissue can be used to repair the cornea in cases of emergency but the tissue is not transparent and does not allow good vision. We hypothesize that frozen grafts are equivalent as fresh grafts when used as carrier for the KPro.


Description:

The Boston Keratoprosthesis (KPro) is a collar-button shaped device made from a specialized clear plastic material. This device is used to replace a diseased and opaque cornea with a clear window so that vision can be improved. KPro surgery is an alternative to a traditional corneal graft and is used when a traditional corneal graft has failed or has a very poor probability of success. During KPro surgery, the KPro needs to be incorporated into a corneal graft before it is sutured to the patient's cornea. The corneal graft serves as a support to the KPro and helps to re-establish vision. The corneas typically used as carriers for the KPro are fresh corneas provided through donors. These fresh corneas are also used in traditional corneal transplantation, without KPro implantation. Due to shortage of fresh corneas in the province of Quebec, this project is interested in evaluating if corneas that have been previously frozen can act as carriers to the KPro. The frozen corneas cannot be used in traditional corneal transplantation surgery because they are not transparent. However, they can act as a support to the KPro, as in this case, it is the KPro and not the corneal graft that re-establishes vision. The use of frozen corneas for KPro surgery has the potential to improve access to corneal donor tissue and improve the wait-times for KPro surgery. 37 patients were be recruited from the Centre Hospitalier de l'Université de Montréal (CHUM), Notre-Dame Hospital between October 2008 and November 2009. Participants were divided into 2 groups: the first group will receive a KPro in a fresh corneal carrier graft while the second group will receive a KPro in a frozen carrier graft. The use of a fresh or frozen corneal graft depended on the availability of fresh tissue on the morning of surgery. 19 patients received a fresh carrier graft and 18 received a frozen carrier graft. Patients were followed on postoperative day 1, week 1 and 2, month 1, 3 and 6 and every 1 to 3 months thereafter up to 2 years. At each follow-up visit, a complete ophthalmological examination was performed, including best-corrected Snellen visual acuity and slit lamp assessment for leaks, tissue necrosis, melts, extrusion, inflammation, retroprosthetic membrane formation and infectious endophthalmitis. The current study aims re-consent patients previously enrolled in this study to prospectively evaluate the long-term outcomes of KPro surgery using either a fresh or frozen carrier graft. IRB approval was obtained from the CHUM. Written informed consent from the concerned patients will be obtained for this extension study during their routine visits at the CHUM Ophthalmology department. Patients in this study will continue their routine follow-up at the frequency determined by their surgeon, which may vary from every 3 to 6 months. Outcome measures include surgical feasibility, level of preoperative and postoperative visual acuity (VA), retention of the device and complications as stated above. Outcomes will be compared at 5 and 10 years.


Recruitment information / eligibility

Status Completed
Enrollment 37
Est. completion date November 2020
Est. primary completion date November 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adult subject over age 18 years - Boston KPro type I indicated - history, slit-lamp findings and B-scan do not suggest endstage glaucoma or significant posterior segment disease - Able to provide informed consent for study inclusion - Sufficiently healthy to undergo surgery and a vigorous post-operative follow-up course - Able to administer eye medications or have a care-giver able and willing to do the same - Corneal blindness with poor prognosis for survival of a traditional penetrating keratoplasty Exclusion Criteria: - Subject under age 18 years - History, slit-lamp findings and B-scan suggest endstage glaucoma or significant posterior segment disease - Not sufficiently healthy to undergo surgery and a vigorous post-operative follow-up course - Unable to administer eye medication or does not have a care-giver willing to do the same

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Boston KPro type I - fresh graft
Boston KPro mounted on fresh corneal carrier graft for implantation
Boston KPro type I surgery - frozen graft
Boston KPro mounted on frozen corneal carrier graft for implantation

Locations

Country Name City State
Canada Centre Hospitalier de l'Université de Montréal Montréal Quebec

Sponsors (2)

Lead Sponsor Collaborator
Marie-Claude Robert Fonds de recherche en ophtalmologie de l'Université de Montréal

Country where clinical trial is conducted

Canada, 

References & Publications (1)

Robert MC, Biernacki K, Harissi-Dagher M. Boston keratoprosthesis type 1 surgery: use of frozen versus fresh corneal donor carriers. Cornea. 2012 Apr;31(4):339-45. doi: 10.1097/ICO.0b013e31823e6110. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Extrusion rate 10 years post-KPro implantation
Secondary Best-corrected visual acuity 10 years
Secondary Retroprosthetic membrane formation 10 years
Secondary Endophthalmitis rate 10 years
Secondary Sterile vitritis rate 10 years
Secondary Intraoperative complications time of surgery
See also
  Status Clinical Trial Phase
Terminated NCT03126903 - A Clinical Study to Evaluate the KeraKlear Keratoprosthesis in Patients With Corneal Opacity N/A
Withdrawn NCT01256489 - Infliximab to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis (SJS/TENS) Phase 1/Phase 2